Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Snap Inc (SNAP) Price & Performance

DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Snap Inc — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.08B), while Snap Inc trades at $5.51 (market cap $9.05B). The key difference: DexCom, Inc. is far larger — about 3.7× Snap Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.

DXCMSNAP
Market Cap
$33.08B$9.05B
Sector
HealthMedia
52-Week High
$89.53$9.09
52-Week Low
$54.84$3.93
Enterprise Value
$32.53B$10.61B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.

Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.

Snap Inc

SNAP trades at $5.33, up 2.3% today, with a bullish technical signal and recent Q2 2026 earnings beating expectations. Revenue grew 19% year-over-year to $1.60 billion, and adjusted EBITDA surged 505%. The stock shows improving operational trends but remains unprofitable, with a net income margin of -4.9% for 2025. Analyst consensus price target is $7.02, suggesting potential upside from current levels.

Outlook hinges on sustained advertising recovery and cost discipline. Risks include persistent losses, high debt, and competitive pressure. Institutional sentiment is mixed, with 38% buy ratings but recent insider selling. The stock offers speculative growth potential if profitability improves, but volatility may persist near-term.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Snap Inc

Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.

Read more on SNAP